Data as of . Holdings from the fund’s latest public SEC N-PORT filing; overlap and active share computed by ETFIQ against the IVV and QQQM books; returns from Tiingo end-of-day prices with distributions reinvested.
IDNA · iShares Genomics Immunology and Healthcare ETF
iShares · Themes desk
Open the live card on ETFIQBy weight, 21% of IDNA's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 99%. The top ten holdings are 48% of the fund across 60 positions, as filed for Apr 30, 2026. Over the year to Sep 4, 2026 the fund returned +78.0% with distributions reinvested against +20.0% for the S&P 500, so a holder was ahead by 58.0 pts. It sits 24.8% below its all-time high of Sep 2, 2021.
| Theme (ETFIQ, editorial) | Genomics and biotech innovation |
|---|---|
| Launched | Jun 13, 2019 |
| Already in the S&P 500, by weight (ETFIQ) | 21.4% |
| Active share vs the S&P 500 (ETFIQ) | 99.1% |
| Already in the Nasdaq-100, by weight (ETFIQ) | 7.3% |
| Active share vs the Nasdaq-100 (ETFIQ) | 99.2% |
| Top ten holdings weight | 47.5% |
| Holdings | 60 |
| Net assets (latest filing) | $160M |
| Holdings as of (SEC N-PORT) | Apr 30, 2026 |
| Top holdings | REVOLUTION MEDICINES, INC. 6.9%, MODERNA, INC. 6.3%, IPSEN SA 5.3%, Bayer Aktiengesellschaft 4.4%, Takeda Pharmaceutical Company Limited 4.2%, MERCK & CO., INC. 4.2%, GSK PLC 4.2%, BioNTech SE 4.1%, Roche Holding AG 4.0%, EXELIXIS, INC. 3.8% |
| 3 months: total return / S&P 500 / gap / Nasdaq-100 gap (ETFIQ) | +37.0% / +4.7% / +32.4 pts / +35.0 pts |
| 6 months: total return / S&P 500 / gap / Nasdaq-100 gap (ETFIQ) | +35.0% / +15.2% / +19.9 pts / +14.8 pts |
| 1 year: total return / S&P 500 / gap / Nasdaq-100 gap (ETFIQ) | +78.0% / +20.0% / +58.0 pts / +52.4 pts |
| 3 years: total return / S&P 500 / gap / Nasdaq-100 gap (ETFIQ) | +82.9% / +78.0% / +4.9 pts / −10.6 pts |
| since launch: total return / S&P 500 / gap / Nasdaq-100 gap (ETFIQ) | +69.5% / +196.2% / −126.7 pts / −240.8 pts |
| Below its all-time high (ETFIQ) | −24.8% |
| Expense ratio (prospectus XBRL) | 0.47% |
| Fee for the part that differs from the S&P 500, active expense ratio (ETFIQ) | 0.47% |
| Closest funds by holdings overlap | GNOM 20%, AGNG 12%, HTEC 11%, HELX 10% |
Questions people ask
- How much of IDNA is already in the S&P 500?
- By its holdings filed for Apr 30, 2026, 21% of IDNA by weight is stocks the S&P 500 already holds. Its active share against the index is 99%, so that share is the part doing something different.
- What does IDNA hold?
- 60 positions as filed for Apr 30, 2026, with the top ten at 48% of the fund. The largest are REVOLUTION MEDICINES, INC. at 6.9%, MODERNA, INC. at 6.3%, IPSEN SA at 5.3%.
- Has IDNA beaten the S&P 500?
- Over the year to Sep 4, 2026 IDNA returned +78.0% with distributions reinvested, against +20.0% for the S&P 500, so it finished ahead of the index by 58.0 points.
- What does IDNA cost?
- The prospectus expense ratio is 0.47% a year. Because 99% of the fund differs from the S&P 500, the fee on that differing part works out at 0.47%.
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Funds near this one
Put this on your own page
The difference bar for IDNA, redrawn every trading night. Free to use with the credit link; paste these two lines into any page or newsletter.
<a href="https://etfiq.com/funds/IDNA.html"><img src="https://etfiq.com/embed/themes/IDNA.svg" alt="IDNA difference bar, ETFIQ" width="640"></a>
<p><a href="https://etfiq.com/funds/IDNA.html">IDNA difference bar, updated daily by ETFIQ</a></p>Cite this page. ETFIQ, IDNA on the themes desk, data as of Sep 4, 2026. https://etfiq.com/funds/IDNA.html Free to use with attribution; the underlying files are at Open data.
ETFIQ is an independent publisher of exchange-traded fund data. It is not a fund issuer, broker-dealer or investment adviser, and it makes no recommendations; sort orders and figures are stated arithmetic on published data. Standards · How to read this desk